PharmaCyte Biotech Inc. (PMCB)
NASDAQ: PMCB
· Real-Time Price · USD
1.04
0.01 (0.97%)
At close: May 20, 2025, 3:59 PM
1.04
0.00%
After-hours: May 20, 2025, 07:31 PM EDT
0.97% (1D)
| Bid | 1.04 |
| Market Cap | 7.14M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 20.25M |
| EPS (ttm) | 1.34 |
| PE Ratio (ttm) | 0.78 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 1.14 |
| Volume | 204 |
| Avg. Volume (20D) | 13,740 |
| Open | 1.05 |
| Previous Close | 1.03 |
| Day's Range | 1.04 - 1.05 |
| 52-Week Range | 1.00 - 2.42 |
| Beta | -0.43 |
About PMCB
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol PMCB
Website n/a
2 years ago · businesswire.com
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase PlanLAS VEGAS--( BUSINESS WIRE )--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”), a biotechnology company focused on evaluating its signature live-cell encapsulation technology, Ce...
2 years ago · businesswire.com
PharmaCyte Biotech Rebukes Iroquois' Commencement of Consent SolicitationLAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature li...
2 years ago · businesswire.com
PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent SolicitationLAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites using its signature li...